PLX51107

DB17543InvestigationalSmall molecule

PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family. PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With...

Mechanism: Pharmacologically active on Bromodomain-containing protein 4 and Bromodomain testis-specific protein
Curator reviewed
Formula / weight: C₂₆H₂₂N₄O₃ · 438.487 g/mol (avg)
Also known as: Benzoic acid, 4-(6-(3,5-dimethyl-4-isoxazolyl)-1-((1s)-1-(2-pyridinyl)ethyl)-1h-pyrrolo(3,2-b)pyridin-3-yl)- · Brd4 inhibitor plx51107
Code names: PLX-51107

Resolves to

Compound

UNIIW758F1L9NDCAS1627929-55-8

Structure

InChIKeyAMSUHYUVOVCWTP-UHFFFAOYSA-NSMILESCC(N1C=C(C2=C1C=C(C=N2)C1=C(C)ON=C1C)C1=CC=C(C=C1)C(O)=O)C1=CC=CC=N1

Targets

O60885BRD4Q58F21BRDT

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with PLX51107, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account